公开(公告)号：US20180244802A1

公开(公告)日：2018-08-30

申请号：US15753642

申请日：2016-08-16

申请人： DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DZNE)

发明人： Harald PRUESS

IPC分类号： C07K16/42 ,  C07K16/28 ,  G01N33/68 ,  G01N33/53 ,  C12N15/115

CPC分类号： C07K16/4208 ,  A61K45/06 ,  C07K16/286 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/115 ,  C12N2310/16 ,  G01N33/5308 ,  G01N33/6854 ,  G01N33/6872 ,  G01N2333/70571

摘要： Subject matter of the present invention is an Antibody or antibody fragment or non-Ig scaffold binding to a binding region of an anti-NMDAR1 antibody and its uses in therapy or diagnosis.

公开(公告)号：US20170362276A1

公开(公告)日：2017-12-21

申请号：US15477907

申请日：2017-04-03

申请人： The Administrators of the Tulane Educational Fund ,  United States Department of Veterans Affairs

发明人： James E. ZADINA ,  Laszlo HACKLER

IPC分类号： C07K7/64 ,  C07K7/56 ,  C07K14/665 ,  G01N33/94 ,  C07K7/06 ,  A61K38/00

CPC分类号： C07K7/64 ,  A61K38/00 ,  C07K7/06 ,  C07K7/56 ,  C07K14/665 ,  G01N33/9486 ,  G01N2333/70571 ,  G01N2333/726 ,  G01N2500/04

摘要： The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.

公开(公告)号：US20170176459A1

公开(公告)日：2017-06-22

申请号：US15388209

申请日：2016-12-22

申请人： GRACE LABORATORIES, LLC

发明人： Svetlana Dambinova ,  Alexander Skoromets

IPC分类号： G01N33/68 ,  A61K38/06

CPC分类号： G01N33/6896 ,  A61K38/06 ,  A61K38/08 ,  G01N33/6875 ,  G01N2333/705 ,  G01N2333/70571 ,  G01N2800/28

摘要： Provided herein are compositions, methods and kits for determining the level of an AMPAR/KAR peptides in a subject. The methods include obtaining a biological sample from the subject and determining a level of one or more AMPAR/KAR peptides selected from the group consisting of GluR1/GluR6_7, GluR2/GluR6_7, GluR3/GluR6_7, GluR1/GluR6, GluR2/GluR7, and any combination thereof in the biological sample.

公开(公告)号：US20170095543A1

公开(公告)日：2017-04-06

申请号：US15150224

申请日：2016-05-09

申请人： Cedars-Sinai Medical Center

发明人： Henry C. Lin ,  Mark Pimentel

IPC分类号： A61K38/54 ,  A61K31/7036 ,  A61K31/43 ,  A61K31/424 ,  A61K31/7048 ,  A61K9/00 ,  A61K31/135 ,  A61K36/534 ,  A61K31/198 ,  A61K31/201 ,  A61K31/138 ,  A61K38/22 ,  A61K38/17 ,  A23L33/00 ,  G01N33/497 ,  G01N33/68 ,  A61K45/06

CPC分类号： A61K38/54 ,  A23L33/40 ,  A23V2002/00 ,  A61B5/0836 ,  A61B5/412 ,  A61B5/415 ,  A61B5/418 ,  A61K9/0053 ,  A61K9/0087 ,  A61K31/135 ,  A61K31/138 ,  A61K31/198 ,  A61K31/201 ,  A61K31/353 ,  A61K31/4045 ,  A61K31/4164 ,  A61K31/4184 ,  A61K31/424 ,  A61K31/43 ,  A61K31/496 ,  A61K31/65 ,  A61K31/7036 ,  A61K31/7048 ,  A61K36/534 ,  A61K38/1796 ,  A61K38/22 ,  A61K38/225 ,  A61K38/2271 ,  A61K45/06 ,  A61K49/0004 ,  A61K51/1206 ,  G01N33/497 ,  G01N33/6893 ,  G01N2033/4977 ,  G01N2333/70571 ,  G01N2800/06 ,  Y10S426/80 ,  Y10S426/801 ,  Y10T436/145555 ,  Y10T436/147777 ,  Y10T436/18 ,  Y10T436/214 ,  Y10T436/22 ,  A61K2300/00

摘要： Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

公开(公告)号：US20160326227A1

公开(公告)日：2016-11-10

申请号：US15023131

申请日：2014-10-16

申请人： INSTITUT D'INVESTIGACIONES BIOMEDIQUES AUGUST PI I SUNYER ,  INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS

发明人： Josep Dalmau

IPC分类号： C07K14/47 ,  G01N33/94 ,  G01N33/564

CPC分类号： C07K14/4713 ,  A61K38/00 ,  G01N33/564 ,  G01N33/9426 ,  G01N2333/70571 ,  G01N2800/2857

摘要： The present invention provides a use of a GABA(A)R, GABA(A)R fragment, or homolog thereof or a cell expressing the GABA(A)R, GABA(A)R fragment, or homolog thereof for the prognosis, diagnosis or treatment of an autoimmune disease in a subject, methods of prognosticating, diagnosing or treating an autoimmune disease, an autoantibody binding to a GABA(A)R, GABA(A)R fragment, or homolog thereof, a method for isolating an antibody binding to a GABA(A)R, GABA(A)R fragment, or homolog thereof, and a test kit, pharmaceutical composition and medical or diagnostic device comprising a GABA(A)R, GABA(A)R fragment, or homolog thereof.

摘要翻译： 本发明提供了GABA（A）R，GABA（A）R片段或其同源物或表达GABA（A）R，GABA（A）R片段或其同源物的细胞用于预后，诊断的用途 或治疗受试者中的自身免疫疾病，预后，诊断或治疗自身免疫疾病的方法，与GABA（A）R，GABA（A）R片段或其同系物结合的自身抗体，分离抗体结合的方法 （A）R，GABA（A）R片段或其同源物，以及包含GABA（A）R，GABA（A）R片段或其同系物的测试试剂盒，药物组合物和医学或诊断装置。

公开(公告)号：US20160228452A1

公开(公告)日：2016-08-11

申请号：US14611143

申请日：2015-01-30

申请人： Korea Advanced Institute of Science and Technology

发明人： Ha Il KIM ,  Sang Kyu PARK

IPC分类号： A61K31/554 ,  A61K31/519 ,  A61K31/496 ,  A61K31/551 ,  A61K31/407 ,  A61K31/445 ,  A61K31/4178 ,  A61K31/46 ,  A61K31/439 ,  A61K31/473 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/166 ,  A61K45/06 ,  G01N33/50 ,  C12Q1/68 ,  A61K31/517

CPC分类号： A61K31/554 ,  A61K31/135 ,  A61K31/166 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/439 ,  A61K31/445 ,  A61K31/46 ,  A61K31/473 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  C12Q1/6883 ,  G01N33/942 ,  G01N2333/70571 ,  G01N2500/04 ,  A61K2300/00

摘要： The present invention relates to a method for preventing or treating a metabolic disease, which comprises inhibiting HTR2A (5-hydroxytryptamine 2A receptor) or HTR3A (5-hydroxytryptamine 3A receptor). The inhibition of HTR3A leads to various advantageous efficacies for therapy of metabolic diseases, including resistance to obesity, decrease of lipid droplet size, increase of expression levels of thermogenic genes, increase of metabolic activities, increase of insulin sensitivity and decrease of LDL cholesterol and leptin.

摘要翻译： 本发明涉及一种预防或治疗代谢性疾病的方法，其包括抑制HTR2A（5-羟色胺2A受体）或HTR3A（5-羟色胺3A受体）。 抑制HTR3A导致代谢疾病治疗的各种有利功效，包括对肥胖的抵抗力，脂滴大小的减少，生热基因的表达水平的增加，代谢活动的增加，胰岛素敏感性的增加和LDL胆固醇和瘦蛋白的降低 。

公开(公告)号：US20160176930A1

公开(公告)日：2016-06-23

申请号：US14974249

申请日：2015-12-18

申请人： United States Department of Veterans Affairs ,  The Administrators of the Tulane Educational Fund

发明人： James E. ZADINA ,  Laszlo HACKLER

IPC分类号： C07K7/64

CPC分类号： C07K7/64 ,  A61K38/00 ,  C07K7/06 ,  C07K7/56 ,  C07K14/665 ,  G01N33/9486 ,  G01N2333/70571 ,  G01N2333/726 ,  G01N2500/04

摘要： The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated amino acid and (ii) a D-amino acid substitution in position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.

摘要翻译： 本发明涉及结合mu（吗啡）阿片受体的环肽激动剂及其在治疗急性和/或慢性疼痛中的用途。 本发明的实施方案涉及内啡肽的环状五肽和六肽类似物，其具有（i）具有酰胺化氨基酸的羧基末端延伸和（ii）位置2的D-氨基酸取代。这些肽类似物显示出降低的耐受性相对 吗啡，与类似的四肽类似物相比增加溶解度，同时保持镇痛与副作用的有利或改善的治疗比。

公开(公告)号：US09358276B2

公开(公告)日：2016-06-07

申请号：US14572037

申请日：2014-12-16

申请人： Cedars-Sinai Medical Center

发明人： Henry C. Lin ,  Mark Pimentel

IPC分类号： A61K49/00 ,  A61K45/00 ,  A61K47/00 ,  A61K38/54 ,  A61B5/00 ,  A61K31/353 ,  A61K31/4184 ,  A61K31/496 ,  A61K38/22 ,  A61K45/06 ,  A61K51/12 ,  G01N33/68 ,  A61K9/00 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7036 ,  A23L1/29 ,  A61K31/198 ,  A61K31/201 ,  A61K31/4045 ,  A61B5/083 ,  G01N33/497

CPC分类号： A61K38/54 ,  A23L33/40 ,  A23V2002/00 ,  A61B5/0836 ,  A61B5/412 ,  A61B5/415 ,  A61B5/418 ,  A61K9/0053 ,  A61K9/0087 ,  A61K31/135 ,  A61K31/138 ,  A61K31/198 ,  A61K31/201 ,  A61K31/353 ,  A61K31/4045 ,  A61K31/4164 ,  A61K31/4184 ,  A61K31/424 ,  A61K31/43 ,  A61K31/496 ,  A61K31/65 ,  A61K31/7036 ,  A61K31/7048 ,  A61K36/534 ,  A61K38/1796 ,  A61K38/22 ,  A61K38/225 ,  A61K38/2271 ,  A61K45/06 ,  A61K49/0004 ,  A61K51/1206 ,  G01N33/497 ,  G01N33/6893 ,  G01N2033/4977 ,  G01N2333/70571 ,  G01N2800/06 ,  Y10S426/80 ,  Y10S426/801 ,  Y10T436/145555 ,  Y10T436/147777 ,  Y10T436/18 ,  Y10T436/214 ,  Y10T436/22 ,  A61K2300/00

摘要： Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

公开(公告)号：US20160068599A1

公开(公告)日：2016-03-10

申请号：US14945831

申请日：2015-11-19

申请人： Trustees of Dartmouth College

发明人： William G. North

IPC分类号： C07K16/28 ,  A61K31/445 ,  A61K31/439

CPC分类号： C07K16/286 ,  A61K31/13 ,  A61K31/439 ,  A61K31/445 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/73 ,  C12N15/1138 ,  C12N15/115 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N2333/70571 ,  A61K2300/00 ,  A61K39/395

摘要： Methods for decreasing proliferation and preventing or treating a neuroendocrine cancer using an N-methyl D-aspartate-associated (NMDA) glutamate receptor antagonists or binding agent, such as an antibody, antibody fragment or peptide aptamer specific for a NMDA glutamate receptor, are disclosed.

摘要翻译： 公开了使用N-甲基D-天冬氨酸相关（NMDA）谷氨酸受体拮抗剂或结合剂，例如对于NMDA谷氨酸受体特异性的抗体，抗体片段或肽适配体来降低增殖和预防或治疗神经内分泌癌的方法 。

公开(公告)号：US20160022658A1

公开(公告)日：2016-01-28

申请号：US14877783

申请日：2015-10-07

申请人： AbbVie Inc.

发明人： Murali Gopalakrishnan ,  Marie P. Honore ,  Chih-Hung Lee ,  John Malysz ,  Jianguo Ji ,  Tao Li ,  Michael R. Schrimpf ,  Kevin B. Sippy ,  David J. Anderson

IPC分类号： A61K31/4439 ,  A61K31/444 ,  G01N33/94 ,  C07D413/04 ,  C07D413/14 ,  A61K45/06 ,  A61K31/4427 ,  A61K31/4709

CPC分类号： A61K31/4439 ,  A61K31/4245 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4709 ,  A61K45/06 ,  C07D413/04 ,  C07D413/14 ,  G01N33/944 ,  G01N2333/70571 ,  A61K2300/00

摘要： The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.

摘要翻译： 本发明涉及包含神经元烟碱性受体配体和α4和bgr2阳性变构调节剂，其使用方法和相关制品的组合物。